Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HS-10365 as first-line treatment for RET fusion-positive advanced or metastatic non-small cell lung cancer
CTR20232270Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hs-10365 in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Oct 2023; status: active.
02
Drugs
hs-10365
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20232270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232270.